Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.60 |
| ▸ | ARG2 | P78540 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343695 | 1.00 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL29278348 | 1.00 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL7902168 | 0.88 | ARG1 (0.59) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL1819025 | 0.86 | BLM (0.56) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL22689266 | 0.85 | ARG1 (0.79) | ARG1ARG2SMN1; SMN2HIF1ASLC6A2 | |
| SCHEMBL8351006 | 0.85 | SMN1; SMN2 (0.69) | ARG1ARG2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL7653153 | 0.84 | ARG1 (0.62) | ARG1ARG2SMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL14478223 | 0.82 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL27469449 | 0.82 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL11265744 | 0.81 | HIF1A (0.60) | ARG1ARG2SMN1; SMN2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6766071-B2 | Device and method for the measurement of the heat of a reaction | AMERSHAM BIOSCIENCES UK LTD. (GB) | 2004-07-20 | — | — | US | claimed |
| US-20030095735-A1 | Device and method for the measurement of the heat of a reaction | GE HEALTHCARE UK LIMITED (GB) | 2003-05-22 | — | — | US | claimed |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-03-10 | — | — | US | disclosed |
| EP-2486229-B1 | APPARATUSES AND METHODS OF MANUFACTURING OILFIELD MACHINES | MI LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3703666-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | Universidade de Santiago de Compostela (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20120245014-A1 | APPARATUSES AND METHODS OF MANUFACTURING OILFIELD MACHINES | M-I L.L.C. | 2012-09-27 | — | — | US | disclosed |
| EP-2486229-A2 | APPARATUSES AND METHODS OF MANUFACTURING OILFIELD MACHINES | M.I L.L, C. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044227-A2 | APPARATUSES AND METHODS OF MANUFACTURING OILFIELD MACHINES | M-I L.L.C. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011026111-A1 | ORAL DELIVERY OF A VACCINE TO THE LARGE INTESTINE TO INDUCE MUCOSAL IMMUNITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-03 | — | — | WO | disclosed |
| US-6766071-B2 | Device and method for the measurement of the heat of a reaction | AMERSHAM BIOSCIENCES UK LTD. (GB) | 2004-07-20 | — | — | US | disclosed |
| US-20030095735-A1 | Device and method for the measurement of the heat of a reaction | GE HEALTHCARE UK LIMITED (GB) | 2003-05-22 | — | — | US | disclosed |
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | ARG1 587/4885ARG2 2005/4885SMN1; SMN2 2935/4885 |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | ARG1 587/4885ARG2 2005/4885SMN1; SMN2 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.